Skip to main content
Log in

T-Zell-Transfer

T cell transfer

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Für eine effektive Tumorabwehr ist das Zusammenspiel verschiedener Immunzellen wichtig. Dabei spielen T-Lymphozyten eine zentrale Rolle. Zytotoxische T-Zellen und T-Helferzellen erkennen sog. Tumorantigene und haben eine synergistische Wirkung bei der Zerstörung von Tumorzellen. In den letzten Jahren wurden Techniken entwickelt, um antigenspezifische T-Zellen in vitro zu generieren, was wiederum Voraussetzung für den adoptiven Transfer ist. Es gibt prinzipiell 3 verschiedene Möglichkeiten: die Verwendung Tumor-infiltrierender Lymphozyten (TIL) als Quelle von tumorreaktiven T-Zellen, die Isolierung tumorreaktiver T-Zellen aus dem peripheren Blut und die Konstruktion von antigenspezifischen T-Zellen. Alle 3 Technologien basieren auf der Generierung von T-Zellen, die spezifisch gegen Tumorantigene gerichtet sind.

Abstract

Interactions between various immune cells are necessary for an effective tumour defence, with T lymphocytes playing a central role. Cytotoxic T cells and T helper cells recognise so called tumour antigens and have a synergistic effect on the destruction of tumour cells. Recently, novel techniques have been developed to produce antigen-specific T cells in vitro, which is a requirement for adoptive transfer. In principle, there are three possibilities: the use of tumour infiltrating lymphocytes (TIL) as a source of tumour-reactive T cells, the isolation of tumour-reactive T cells from the peripheral blood, and the construction of antigen-specific T cells. All three technologies are based on the generation of T cells which are reactive with the tumour antigen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Dudley ME, Wunderlich J, Robbins PF et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854

    Article  CAS  PubMed  Google Scholar 

  2. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. PNAS 99:16168–16173

    Google Scholar 

  3. Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R, Mackensen A (2003) Survival and tumor localization of adoptively transferred melan-A-specific T cells in melanoma patients. J Immuno 170:2161–2169

    Google Scholar 

  4. Bernhard H, Schmidt B, Busch DH, Peschel C (2005) Isolation and expansion of tumor-reactive cytotoxic T cell clones for adoptive immunotherapy. In: Ludewig B, Hoffmann MW (eds) Methods Mol Med, Vol. 109, Humana Press Inc., pp 175–184

  5. Stanislawski T, Voss R-H, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RLH, Melief CJ, Huber C, Stauss HJ, Theobald M (2001) Circumventing tolerance to a human MDM 2-derived tumor antigen by TCR gene transfer. Nature Immunol 2:962–970

    Google Scholar 

  6. Schumacher TNM (2002) T-cell-receptor gene therapy. Nat Rev Immunol 2:512–519

    Google Scholar 

  7. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients Blood, 76:2462–2465

  8. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, and Heslop HE (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin’s disease. J Exp Med 200:1623–1633

    Google Scholar 

  9. Marijt WA, Heemskerk, MHM, Kloosterboer FM, Goulmy E, Kester MGD, van der Hoorn MAWG, van Luxemburg-Heys SAP, Hoogeboon M, Mutis T, Dijfhout JW, van Rood JJ, Willemze R, Falkenburg JHF (2003) Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. PNAS 100:2742–2747

    Google Scholar 

  10. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of „tumor escape“ phenotypes. Nature Immunol 3:999–1005

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Bernhard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernhard, H. T-Zell-Transfer. Onkologe 11, 514–517 (2005). https://doi.org/10.1007/s00761-005-0872-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-005-0872-y

Schlüsselwörter

Keywords

Navigation